BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Cappella Medical Devices Ltd Announces Excellent Long Term Follow-Up Clinical Data on its Sideguard(R) Technology


10/12/2011 8:53:34 AM

GALWAY, Ireland--(BUSINESS WIRE)--Cappella Medical Devices Ltd (Cappella), a medical device company developing dynamic solutions for the treatment of coronary bifurcation disease, today announced initial long term follow up data for its innovative Sideguard® coronary sidebranch stent from Manchester Royal Infirmary in Manchester, United Kingdom. Long term follow up data on the Sideguard stent was obtained from 38 patients that received the stent as early as March 2010. The stent was successfully placed in all 38 patients. There were no peri-procedural complications and MACE rates were 5.3% at 1 year follow up.

This initial data represents one of the largest single-center clinical experiences to date with the Sideguard technology. The Sideguard was developed to protect the ostium of the sidebranch offering interventional cardiologists a dynamic, effective, and easy-to-use solution in the treatment of bifurcation disease. Results from this single center experience confirmed that preservation of the sidebranch of diseased coronary arteries by protecting the ostium has short and long term benefits.

Dr. Farzin Fath-Ordoubadi, Consultant Cardiologist and Cath Lab Director at the Heart Centre, Manchester Royal Infirmary commented, “The Sideguard stent can be used to treat complex bifurcation lesions in a straight forward manner, with excellent clinical outcomes. The one year MACE rate of 5.3% validates the fact that a dedicated bifurcation technology that protects the ostium of the sidebranch and preserves the sidebranch is, and will be, an ideal solution for patients with true bifurcation disease.” This exciting data is corroborated by the early data coming from the real world, multi centre Sideguard One Registry. The data coming from this registry on 250 patients treated with the Sideguard device is expected to be published early next year.

Up to 30% of all PCI patients have bifurcation disease yet there has not been one proven dedicated treatment solution. Treating these patients has always been a challenge for physicians due to the complex anatomy of the coronary sidebranch. Dr. Art Rosenthal, Executive Vice Chairman and President of R&D, stated, “Conventional procedures forced physicians to treat the bifurcation with either two stents that weren’t intended for this use, or one main vessel stent that has limitations in terms of ostial protection and sidebranch preservation. MACE for existing bifurcation solutions have been documented to be 8% in the BBC-ONE study, so this initial long term MACE of 5.3% with the Sideguard is very encouraging. We are confident that these positive results are in part due to the Sideguard platform that scaffolds the ostium reducing plaque and carina shift while preserving the sidebranch. This data validates the unique advantages of the Cappella Sideguard technology. Additional long term follow up clinical data including interim results of the full multi-center Sideguard registry, of which Manchester Royal Infirmary is part of, will be presented over the next several months.”

About Cappella Medical Devices

Cappella, Inc. is a medical device company that develops novel solutions for the treatment of complex coronary artery disease (CAD) focused on protecting the coronary sidebranch arteries. Cappella’s Sideguard® coronary sidebranch technology offers interventional cardiologists a straightforward, effective, and easy to use solution that preserves the sidebranch of diseased coronary arteries by protecting the ostium while minimizing plaque shift. The Sideguard delivery system features a proprietary split-sheath, balloon released, technology that ensures precise placement on the ostial borderline. The Sideguard self-expanding, nitinol, stent promotes continuous wall apposition and positive remodelling and its unique trumpet-shaped design conforms to varying characteristics of the sidebranch ostium. The Cappella Sideguard system is currently CE mark approved and is being distributed throughout Europe and South America. Cappella Medical Devices Ltd., Galway, Ireland is the R&D and manufacturing subsidiary of Cappella, Inc. For more information, please visit the Cappella Medical Systems website at www.cappella-med.com.

Contacts

Cappella Medical

David Blossom, +353 (0) 91 758 939

dblossom@cappella.ie


Read at BioSpace.com


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->